# A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell 

Source: https://onco.cc/trials/nct06230224/  
OnCo record `nct06230224` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Odronextamab, Ifosfamide, Carboplatin in hodgkin lymphoma and non-hodgkin lymphoma, run by Regeneron Pharmaceuticals, active and no longer recruiting.

## Summary

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma is a phase 3 interventional study registered as NCT06230224 by Regeneron Pharmaceuticals, with 216 participants enrolled, started 2024-02-15 and due to reach its primary completion in 2028-05-29. Interventions recorded: Odronextamab, Ifosfamide, Carboplatin, Etoposide, Rituximab. Conditions listed: B-Cell Non-Hodgkin Lymphoma (B-NHL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06230224
- Phase: 3
- Setting: A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 216

## Sources

- ClinicalTrials.gov NCT06230224: https://clinicaltrials.gov/study/NCT06230224

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Etoposide](https://onco.cc/drugs/etoposide/), [Ifosfamide](https://onco.cc/drugs/ifosfamide/), [Odronextamab](https://onco.cc/drugs/odronextamab/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct06230224.json